September 16th 2020EP. 1: Economic Burden of Cardiovascular Disease
September 16th 2020EP. 2: Risk Assessment for Cardiovascular Disease
September 16th 2020EP. 3: LDL Cholesterol Lowering and CV Risk
September 16th 2020EP. 4: Cardiovascular Risk Management
September 16th 2020EP. 5: Dyslipidemia: Strategies Used to Reduce CV Risk
September 16th 2020EP. 6: Statin Therapy for LDL Reduction and CV Risk
September 16th 2020EP. 7: Statin Therapy: Risk for Future CV Events
September 16th 2020EP. 8: PCSK9 Inhibitors and CV Risk
September 16th 2020EP. 9: Dyslipidemia: Cost-Utilization of PCSK9 Inhibitors
September 16th 2020EP. 10: Targeting Triglycerides to Reduce CV Risk
September 16th 2020EP. 11: The REDUCE-IT Study and CV Risk
September 16th 2020EP. 12: Interim Analysis of EVAPORATE
September 16th 2020EP. 13: Coronary Plaque Regression and CV Risk
September 16th 2020EP. 14: Implications for Treating Patients With Icosapent Ethyl
September 16th 2020EP. 15: Cost-Effectiveness and Cardiovascular Risk
September 16th 2020EP. 16: Cardiovascular Disease Treatment Decisions and Cost
September 16th 2020EP. 17: CV Risk Reduction and Coverage of Therapies
September 16th 2020EP. 18: Cost-Effectiveness Data and Pricing of Icosapent Ethyl
September 16th 2020EP. 19: CVD: Cost-Effectiveness Data and Treatment Selection
September 16th 2020EP. 20: Clinical Pathways for Cardiovascular Disease Management
September 16th 2020EP. 21: Better Strategies to Reduce Cardiovascular Events
